Cancer Genetics, Inc. CGIX
No live quote for CGIX yet.
Analyst view
Consensus: hold
Hold
Price target (mean) —
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy0
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 1
- 2 months ago 1
- 3 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | -4.80 | 0.0% | 10.77M | +40.5% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | -3.90 | 0.0% | 11.24M | +59.7% | 0 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 46.82M | +70.4% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 54.25M | +15.9% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2020 | Maxim Group | Downgrade | Buy | Hold |
| Nov 25, 2020 | Maxim Group | Initiated | — | Buy |
| Nov 25, 2020 | Dawson James | Initiated | — | Buy |
| Nov 25, 2020 | Benchmark | Initiated | — | Speculative Buy |
| Nov 25, 2020 | Rodman & Renshaw | Initiated | — | Buy |
| Nov 25, 2020 | Aegis Capital | Maintained | — | Buy |
| Nov 25, 2020 | Janney Capital | Downgrade | Buy | Neutral |
| Nov 25, 2020 | Janney Capital | Initiated | — | Buy |
| Nov 25, 2020 | Cantor Fitzgerald | Maintained | — | Buy |
| Nov 25, 2020 | Cantor Fitzgerald | Initiated | — | Buy |
| Nov 25, 2020 | Aegis Capital | Maintained | — | Buy |
| Nov 25, 2020 | Aegis Capital | Initiated | — | Buy |
| Nov 25, 2020 | Feltl & Co. | Initiated | — | Strong Buy |